1-2 of 2
Monelle Tamegnon
Close
Sort by
Journal Articles

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Clinical Trials & Observations
Loretta J. Nastoupil, Georg Hess, Miguel A. Pavlovsky, Iwona Danielewicz, Jane Freeman, Alejandro Martin García-Sancho, Valeria Glazunova, Andrew Grigg, Jing-Zhou Hou, Ann Janssens, Seok Jin Kim, Zvenyslava Masliak, Pam McKay, Francesco Merli, Wataru Munakata, Hirokazu Nagai, Muhit Özcan, Meir Preis, Tingyu Wang, Melissa Rowe, Monelle Tamegnon, Rui Qin, Todd Henninger, Madeliene Curtis, Donne Bennett Caces, Catherine Thieblemont, Gilles Salles
Journal: Blood Advances
Blood Adv (2023) 7 (22): 7141–7150.
https://doi.org/10.1182/bloodadvances.2023010298
Published: 2023
Includes: Supplemental data
Journal Articles

Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial

Clinical Trials & Observations
G. A. Amos Burke, Luciana Vinti, Edita Kabickova, Auke Beishuizen, Nurdan Tacyildiz, Anne Uyttebroeck, Hyoung Jin Kang, Flavio Luisi, Véronique Minard-Colin, Birgit Burkhardt, Monelle Tamegnon, Steven Sun, Madeliene Curtis, Sanjay Deshpande, Kerri Nottage, Angela Howes, Srimathi Srinivasan, Deepa Bhojwani, Robin Norris, Mitchell Cairo
Journal: Blood Advances
Blood Adv (2023) 7 (4): 602–610.
https://doi.org/10.1182/bloodadvances.2022008802
Published: 2023
Includes: Supplemental data